KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Taxes (2016 - 2025)

Historic Change in Taxes for Jazz Pharmaceuticals (JAZZ) over the last 14 years, with Q3 2025 value amounting to $12.7 million.

  • Jazz Pharmaceuticals' Change in Taxes rose 51595.74% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.2 million, marking a year-over-year increase of 33463.17%. This contributed to the annual value of -$14.7 million for FY2024, which is 15845.36% down from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Change in Taxes stood at $12.7 million, which was up 51595.74% from $46.3 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Change in Taxes peaked at $46.3 million during Q2 2025, and registered a low of -$46.5 million during Q2 2021.
  • In the last 5 years, Jazz Pharmaceuticals' Change in Taxes had a median value of $12.7 million in 2025 and averaged $3.4 million.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Change in Taxes plummeted by 226440.79% in 2023 and then soared by 135907.94% in 2025.
  • Jazz Pharmaceuticals' Change in Taxes (Quarter) stood at -$24.7 million in 2021, then skyrocketed by 93.84% to -$1.5 million in 2022, then tumbled by 2264.41% to -$35.9 million in 2023, then rose by 3.06% to -$34.8 million in 2024, then skyrocketed by 136.56% to $12.7 million in 2025.
  • Its last three reported values are $12.7 million in Q3 2025, $46.3 million for Q2 2025, and $13.0 million during Q1 2025.